Sodium taurocholate cotransporting polypeptide( NTCP) was identified as the receptor for hepatitis B virus( HBV) infection in2012. The finding of HBV receptor has provided a new target for the development of new anti- HBV drugs. This article describes the bottleneck of research on HBV infection,as well as the significance of the finding of HBV and its expression regulation. Over the past two years,studies have shown that a variety of agents can block the receptor function of NTCP and then inhibit HBV entry efficiently. The inhibitors of HBV entry have become a major concept in the development of new anti- HBV drugs and may be one of future strategies for radical treatment of chronic hepatitis B.
DownLoad: